Experience With Candidemia by Candida Parapsilopsis in 203 BMT Recipients Undergoing Different Antifungal Prophylactic Therapies at “Ramon Y Cajal” Hospital in Madrid
| Antifungal Prophylaxis . | Nystatin . | Fluconazole . | Itraconazole . |
|---|---|---|---|
| . | (105 IU/kg⋅d; orally) . | (100 mg/d; orally) . | (400 mg/d; orally) . |
| No. of patients | 75 | 78 | 50 |
| Age in yr (median and range) | 30 (15-50) | 41 (19-67) | 39 (16-66) |
| Disease | |||
| Acute leukemia | 39 | 11 | 10 |
| Chronic leukemia | 10 | 10 | 5 |
| Lymphoma | 18 | 3 | 21 |
| Myeloma | 3 | 26 | 9 |
| Solid tumors | 0 | 25 | 5 |
| Others | 5 | 3 | 0 |
| Source | |||
| Marrow | 66 | 21 | 7 |
| Peripheral blood | 9 | 57 | 43 |
| Donor | |||
| Allogenic | 50 | 16 | 7 |
| Autologous | 25 | 62 | 43 |
| Day of neutrophil engraftment* | 18.85 ± 1.38 | 15.7 ± 1.08 | 14 ± 1.26 |
| 5-Days actuarial probability of C parapsilopsis infection* | 7.46 ± 1.18 | 4.17 ± 0.87 | 4.55 ± 1.03 |
| Antifungal Prophylaxis . | Nystatin . | Fluconazole . | Itraconazole . |
|---|---|---|---|
| . | (105 IU/kg⋅d; orally) . | (100 mg/d; orally) . | (400 mg/d; orally) . |
| No. of patients | 75 | 78 | 50 |
| Age in yr (median and range) | 30 (15-50) | 41 (19-67) | 39 (16-66) |
| Disease | |||
| Acute leukemia | 39 | 11 | 10 |
| Chronic leukemia | 10 | 10 | 5 |
| Lymphoma | 18 | 3 | 21 |
| Myeloma | 3 | 26 | 9 |
| Solid tumors | 0 | 25 | 5 |
| Others | 5 | 3 | 0 |
| Source | |||
| Marrow | 66 | 21 | 7 |
| Peripheral blood | 9 | 57 | 43 |
| Donor | |||
| Allogenic | 50 | 16 | 7 |
| Autologous | 25 | 62 | 43 |
| Day of neutrophil engraftment* | 18.85 ± 1.38 | 15.7 ± 1.08 | 14 ± 1.26 |
| 5-Days actuarial probability of C parapsilopsis infection* | 7.46 ± 1.18 | 4.17 ± 0.87 | 4.55 ± 1.03 |
Expressed as mean ± SE.